Why the study?
The study evaluated the formulation of synthetic IGF-1 (pIGF-1) in PLGA microparticles for cardiac applications.
Synthetic IGF-1 encapsulated in PLGA microparticles and hyaluronic acid hydrogel retains bioactivity and promotes c-kit+ cell proliferation, showing potential for loco-regional delivery to damaged myocardium.
May support preclinical cardiac delivery testing of IGF-1 PLGA MPs; leaves open in vivo retention and clinical translation.
Aim: The aim of this study was to evaluate the formulation of a synthetic IGF-1 (pIGF-1) in PLGA microparticles (MP).Methods: Poly (lactic-co-glycolic acid) (PLGA) MPs loaded with pIGF-1 were prepared, characterised and evaluated using double emulsion solvent evaporation method.Results: Spherical MPs showed an average particle size of 2 µm, encapsulation efficiency (EE) of 67% and 50% degradation over 15 days. With a view to enhancing retention in the myocardium, the MP formulation was encapsulated in a cross-linked hyaluronic acid hydrogel. pIGF-1 released from MPs and from MPs suspended in hyaluronic acid hydrogel remained bioactive, determined by a significant increase in cellular proliferation of c-kit+ cells.Conclusion: This formulation has potential for loco-regional delivery to damaged myocardium to promote the survival of cardiomyocytes.
No takes yet. Share an insight, caveat, or question.
Hameed et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: